Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Not applicable Interventional Accepts healthy volunteers
Conditions
Stroke, Ischemic, Quadrantanopia, Hemianopsia, Homonymous, Hemianopia, Homonymous, Hemianopia, Hemianopsia, Occipital Lobe Infarct, Visual Field Defect, Peripheral, Vision Loss Partial, Quadrantanopsia, Stroke Hemorrhagic
Interventions
Virtual Reality Driving Task
Other
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
243
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 22, 2026, 2:45 AM EDT
Completed No phase listed Observational Results available
Conditions
Cerebral Ischemia
Interventions
Casmed Fore-Sight Elite, Non-invasive Cardiac Output Monitor (NICOM)
Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Cardiovascular Diseases, Atrial Fibrillation, Abnormal Heart Rhythms, Cardiac Arrest, Heart Attack, Myocardial Infarction, Coronary Heart Disease, Heart Failure, Stroke, Cerebrovascular Accident
Interventions
Targeted digital intervention
Other
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
49,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Ischemic Stroke, Chronic Stroke, Hemiparesis, Arm Paralysis
Interventions
CTX0E03 Drug Product and delivery device, Placebo
Combination Product · Drug
Lead sponsor
ReNeuron Limited
Industry
Eligibility
35 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced May 22, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
Conditions
Vision Loss Partial, Vision; Loss, Both Eyes, Hemianopia Homonymous, Hemianopia, Quadrantanopia, Stroke, Ischemic, Stroke - Occipital Infarction, Cortical Blindness
Interventions
Training in the Blind Field
Device
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Ischemic Stroke, Blood Pressure
Interventions
Phenylephrine, Norepinephrine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Interventions
Colchicine 0.5 MG Oral Tablet, Colchicine-Placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
6,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
New Haven, Connecticut • Gainesville, Florida • Tampa, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Stroke, Aphasia, Aphasia Following Cerebral Infarction
Interventions
Transcranial Magnetic Stimulation (TMS), Modified Constraint Induced Language Therapy (mCILT)
Device · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 22, 2026, 2:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
Conditions
Congenital Hemiparesis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Stroke, Acute, Cerebral Infarction
Interventions
Endovascular Thrombectomy, Trevo Retriever, Solitaire™ FR Revascularization Device, Penumbra thrombectomy system, Covidien MindFrame Capture Revascularization Device
Procedure · Device
Lead sponsor
Gregory W Albers
Other
Eligibility
18 Years to 90 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Patent Foramen Ovale, Cryptogenic Stroke, Embolic Infarction
Interventions
intravenous access in greater saphenous vein compared to upper extremity site.
Diagnostic Test
Lead sponsor
St. John's Hospital
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Maple Grove, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Vascular Death, Myocardial Infarction, Stroke, Cardiac Surgery
Interventions
Not listed
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
15,989 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Cerebral Stroke
Interventions
Reaching Task
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Stroke, Ischemia, Infarction
Interventions
CNTO 0007 or placebo (Stage A), CNTO 0007 or placebo (Stage B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Up to 45 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Cerebrovascular Disease, Ischemic Stroke, Transient Ischemic Attack, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage, Vascular Dementia, Anoxic Brain Injury, Unruptured Intracranial Aneurysm, Carotid Artery Stenosis Symptomatic, Asymptomatic Carotid Artery Stenosis, Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage, Cerebral Venous Thrombosis, Moyamoya Disease, Fibromuscular Dysplasia, Subarachnoid Hemorrhage, Leukoaraiosis, Arteriovenous Fistula, Reversible Cerebral Vasoconstriction Syndrome, CADASIL
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Stroke, Ischemia
Interventions
EmboTrap® Revascularization Device
Device
Lead sponsor
Neuravi Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Los Angeles, California • San Jose, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
48,262 participants
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Stroke, Acute
Interventions
hypothermia and anti-shivering treatment, Group1: IV t-PA and normothermia
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years to 82 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced May 22, 2026, 2:45 AM EDT
Conditions
Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
21,379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
250
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced May 22, 2026, 2:45 AM EDT